KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS(G12C) mutation Meeting Abstract
| Authors: | Bekaii-Saab, T. S.; Spira, A. I.; Yaeger, R.; Buchschacher, G. L.; McRee, A. J.; Sabari, J. K.; Johnson, M. L.; Barve, M. A.; Hafez, N.; Velastegui, K.; Christensen, J. G.; Kheoh, T.; Der-Torossian, H.; Rybkin, I. I. |
| Abstract Title: | KRYSTAL-1: Updated activity and safety of adagrasib (MRTX849) in patients (Pts) with unresectable or metastatic pancreatic cancer (PDAC) and other gastrointestinal (GI) tumors harboring a KRAS(G12C) mutation |
| Meeting Title: | 2022 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2022 Jan 20-22 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-01 |
| Language: | English |
| ACCESSION: | WOS:000770995900504 |
| DOI: | 10.1200/JCO.2022.40.4_suppl.519 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: 519 -- Meeting was conducted online as well as in person -- Source: Wos |
